Oncimmune losses deepen on higher R&D and administrative spending

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 08:26

Immunodiagnostics system supplier Oncimmune Holdings said its annual losses deepened as it increased R&D spending.

Pre-tax losses for the year through November amounted to £3.9m, compared to losses of £2.8m on-year.

R&D spending rose to £0.7m, from £0.5m, while administrative expenses also rose.

Revenue nudged up to £121k, from £77k).

'Aligned with the forward strategy, and with the support of Oncimmune's new Scientific Board, our R&D programme has been focused on exploring the potential of tumour-related antibodies as combined and complementary diagnostic tests,' chief executive Adam Hill said.

'Our commercial effort has concentrated on developing propositions for the diagnostic and pharmaceutical industry to maximise the latent potential of Oncimmune's immunogenic protein platform.'

At 8:26am: (LON:ONC) Oncimmune Holdings Plc share price was -8p at 88.5p


Related content

Oncimmune secures €8.5m credit facility from IPF Management

Immunodiagnostics group Oncimmune said it had secured a new €8.5m credit facility from IPF Management.

Oncimmune said it would immediately draw down an initial €5m...

Fri, 20/09/2019 - 07:44


Oncimmune presents positive test results at Barcelona conference

Oncimmune Holdings said it had presented positive study data at an industry conference in Barcelona.

The data were presented by professor Frank Sullivan, the chief...

Mon, 09/09/2019 - 09:30


Oncimmune distributor inks sales agreement in Spain

Immunodiagnostics group Oncimmune Holdings said that its existing distributor in Spain and Portugal had signed an agreement with Spanish private healthcare company Vithas Group.

The...

Mon, 15/07/2019 - 07:49


Oncimmune confident of profitable growth amid positive study results, distribution pacts

Immunodiagnostics group Oncimmune Holdings said it was confident of being able to generate 'material profitable revenues', thanks to several business developments.

The company had earlier...

Wed, 26/06/2019 - 09:03


Oncimmune reports positive results from early lung cancer detection study

Immunodiagnostics group Oncimmune Holdings said it had gathered positive results from a study in Scotland of its early lung-cancer detection technology.

The study recruited 12,210...

Tue, 04/06/2019 - 09:01